Stifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at H.C. WainwrightFebruary 14, 2018 7:16 AM Tetraphase Pharmaceuticals (TTPH) PT Lowered to $8 at Piper JaffrayFebruary 14, 2018 6:15 AM Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at B.Riley/FBR, 'IGNITE3 Failure Limits but Does Not Quash Eravacycline Opportunity'February 14, 2018 4:29 AM BMO Capital Downgrades Tetraphase Pharmaceuticals (TTPH) to Market PerformFebruary 14, 2018 4:05 AM After-Hours Stock Movers 02/13: (FOSL) (CMG) (TWLO) Higher; (TTPH) (NMM) (PIRS) Lower (more...)February 13, 2018 6:03 PM Form 8-K TETRAPHASE PHARMACEUTICA For: Feb 13February 13, 2018 4:22 PM Tetraphase Pharma (TTPH) IGNITE3 Phase 3 Clinical Trial of Eravacycline in cUTI Failed to Meet Co-Primary EndpointsFebruary 13, 2018 4:02 PM Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)February 13, 2018 4:01 PM